Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantheus (DE:0L8)
FRANKFURT:0L8
Holding DE:0L8?
Track your performance easily
0L8 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€46.59 - €114.30
Previous CloseN/A
Volume0.00
Average Volume (3M)53.00
Market Cap
$6.25B
Enterprise Value€7.77B
Total Cash (Recent Filing)$51.18M
Total Debt (Recent Filing)$274.46M
Price to Earnings (P/E)15.3
Beta0.37
Next Earnings
Feb 20, 2025EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.02
Shares Outstanding69,526,840
10 Day Avg. Volume66
30 Day Avg. Volume53
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.58
Price to Cash Flow (P/CF)19.40
P/FCF Ratio41.50
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue5.19
Enterprise Value/Gross Profit10.96
Enterprise Value/Ebitda17.67
Forecast
1Y Price Target
€128.10Price Target Upside38.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Lantheus News
PremiumCompany Announcements
Lantheus Acquires Life Molecular Imaging for $350 Million
PremiumCompany Announcements
Lantheus Announces Departure of Chief Medical OfficerBulls Say, Bears Say
Bulls Say
Acquisition And Market ExpansionThe acquisition of Life Molecular Imaging provides Lantheus with an approved beta amyloid imaging agent and a tau diagnostic, which should accelerate the commercial runway for their Alzheimer's portfolio by a year.
Regulatory And Reimbursement DevelopmentsThe final CMS rule essentially puts to bed risk concerns around the reimbursement status of Pylarify, hence avoiding a worst-case scenario for reimbursement to fall from the current ~$5.2k level to sub ~$1k per test.
Stock Valuation And Growth PotentialLNTH shares offer an attractive entry point as the market is underestimating Pylarify's growth potential.
Bears Say
Pricing And CompetitionRecently signed multi-year contracts reflect higher volumes in conjunction with lower average selling prices, likely due to the initial CMS proposal and new competition.
Product Growth ConcernsWeakness in LNTH's share price has been driven by concern over PYLARIFY's growth trajectory and disappointment over the updated SPLASH results.
Sales And EarningsThe updated annual guidance implied a softer-than-anticipated fourth quarter in both sales and EPS.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.11% Insiders
37.42% Mutual Funds
2.36% Other Institutional Investors
31.51% Public Companies and Individual Investors
0L8 FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was €46.59 and its highest was €114.30 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $6.25B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Feb 20, 2025 which is in 36 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Nov 06, 2024. The company reported €1.659 earnings per share for the quarter, beating the consensus estimate of €1.518 by €0.14.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.5.
How many shares outstanding does Lantheus have?
Lantheus has 69,526,840 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of €1.659 in its last earnings report, beating expectations of €1.518. Following the earnings report the stock price went up 0.946%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in DE:0L8
---
Lantheus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€128.10 (38.87% Upside)
€128.10 (38.87% Upside)
Blogger Sentiment
Bullish
DE:0L8 Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
64.68%
12-Months-Change
Fundamentals
Return on Equity
45.53%
Trailing 12-Months
Asset Growth
34.70%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
---
0L8 Company Deck
---
0L8 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong growth in flagship products like PYLARIFY and DEFINITY, boosted by strategic initiatives and positive regulatory developments. However, these were slightly tempered by sequential revenue declines and challenges with clinical trials for PNT2002. Overall, the financial performance and strategic advancements support a positive outlook.Read More>---
0L8 Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
---
0L8 Stock 12 Month Forecast
Average Price Target
€128.10
▲(38.87% Upside)
Technical Analysis
Lantheus
―
Exact Sciences
―
Guardant Health
―
Natera
―
QuidelOrtho
―
Fulgent Genetics
―
Telesis Bio
―
Best Analysts Covering 0L8
1 Year
1 Year Success Rate
20/28 ratings generated profit
1 Year Average Return
+54.40%
assigned a buy rating 2 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +54.40% per trade.
---